Literature DB >> 18555035

Diffusion-weighted magnetic resonance imaging: a potential non-invasive marker of tumour aggressiveness in localized prostate cancer.

N M deSouza1, S F Riches, N J Vanas, V A Morgan, S A Ashley, C Fisher, G S Payne, C Parker.   

Abstract

AIM: To evaluate diffusion-weighted magnetic resonance imaging (DW-MRI) as a marker for disease aggressiveness by comparing tumour apparent diffusion coefficients (ADCs) between patients with low- versus higher-risk localized prostate cancer.
METHOD: Forty-four consecutive patients classified as low- [n = 26, stageT1/T2a, Gleason score < or = 6, prostate-specific antigen (PSA)< 10 (group 1)] or intermediate/high- [n = 18, stage > or = T2b and/or Gleason score > or = 7, and/or PSA > 10 (group 2)] risk, who subsequently were monitored with active surveillance or started neoadjuvant hormone and radiotherapy, respectively, underwent endorectal MRI. T2-weighted (T2W) and DW images (5 b values, 0-800 s/mm(2)) were acquired and isotropic ADC maps generated. Regions of interest (ROIs) on T2W axial images [around whole prostate, central gland (CG), and tumour] were transferred to ADC maps. Tumour, CG, and peripheral zone (PZ = whole prostate minus CG and tumour) ADCs (fast component from b = 0-100 s/mm(2), slow component from b = 100-800 s/mm(2)) were compared.
RESULTS: T2W-defined tumour volume medians, and quartiles were 1.2 cm(3), 0.7 and 3.3 cm(3) (group 1); and 6 cm(3), 1.3 and 16.5 cm(3) (group 2). There were significant differences in both ADC(fast) (1778 +/- 264 x 10(-6) versus 1583 +/- 283 x 10(-6) mm(2)/s, p = 0.03) and ADC(slow) (1379 +/- 321 x 10(-6) versus 1196 +/- 158 x 10(-6) mm(2)/s, p = 0.001) between groups. Tumour volume (p = 0.002) and ADC(slow) (p = 0.005) were significant differentiators of risk group.
CONCLUSION: Significant differences in tumour ADCs exist between patients with low-risk, and those with higher-risk localized prostate cancer. DW-MRI merits further study with respect to clinical outcomes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18555035     DOI: 10.1016/j.crad.2008.02.001

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  69 in total

1.  Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer.

Authors:  Hashim U Ahmed; Oguz Akin; Jonathan A Coleman; Sarah Crane; Mark Emberton; Larry Goldenberg; Hedvig Hricak; Mike W Kattan; John Kurhanewicz; Caroline M Moore; Chris Parker; Thomas J Polascik; Peter Scardino; Nicholas van As; Arnauld Villers
Journal:  BJU Int       Date:  2011-11-11       Impact factor: 5.588

Review 2.  Diffusion weighted imaging in prostate cancer.

Authors:  Cher Heng Tan; Jihong Wang; Vikas Kundra
Journal:  Eur Radiol       Date:  2010-10-09       Impact factor: 5.315

3.  Prostate cancer managed with active surveillance: role of anatomic MR imaging and MR spectroscopic imaging.

Authors:  Vincent Fradet; John Kurhanewicz; Janet E Cowan; Alexander Karl; Fergus V Coakley; Katsuto Shinohara; Peter R Carroll
Journal:  Radiology       Date:  2010-05-26       Impact factor: 11.105

4.  Diffusion-weighted magnetic resonance imaging for prediction of tumor response to neoadjuvant chemoradiotherapy using irinotecan plus S-1 for rectal cancer.

Authors:  Hiroshi Doi; Naohito Beppu; Takashi Kato; Masashi Noda; Hidenori Yanagi; Naohiro Tomita; Norihiko Kamikonya; Shozo Hirota
Journal:  Mol Clin Oncol       Date:  2015-07-21

5.  Diffusion-weighted magnetic resonance imaging for predicting the response of rectal cancer to neoadjuvant concurrent chemoradiation.

Authors:  Gang Cai; Ye Xu; Ji Zhu; Wei-Lie Gu; Shuai Zhang; Xue-Jun Ma; San-Jun Cai; Zhen Zhang
Journal:  World J Gastroenterol       Date:  2013-09-07       Impact factor: 5.742

6.  Multiparametric 3T endorectal mri after external beam radiation therapy for prostate cancer.

Authors:  Antonio C Westphalen; Galen D Reed; Phillip P Vinh; Christopher Sotto; Daniel B Vigneron; John Kurhanewicz
Journal:  J Magn Reson Imaging       Date:  2012-04-25       Impact factor: 4.813

7.  The role of magnetic resonance imaging (MRI) in focal therapy for prostate cancer: recommendations from a consensus panel.

Authors:  Berrend G Muller; Jurgen J Fütterer; Rajan T Gupta; Aaron Katz; Alexander Kirkham; John Kurhanewicz; Judd W Moul; Peter A Pinto; Ardeshir R Rastinehad; Cary Robertson; Jean de la Rosette; Rafael Sanchez-Salas; J Stephen Jones; Osamu Ukimura; Sadhna Verma; Hessel Wijkstra; Michael Marberger
Journal:  BJU Int       Date:  2013-11-13       Impact factor: 5.588

Review 8.  Hierarchical clustering method to improve transrectal ultrasound-guided diffuse optical tomography for prostate cancer imaging.

Authors:  Venkaiah C Kavuri; Hanli Liu
Journal:  Acad Radiol       Date:  2014-02       Impact factor: 3.173

9.  Relationship between T2 relaxation and apparent diffusion coefficient in malignant and non-malignant prostate regions and the effect of peripheral zone fractional volume.

Authors:  C J Simpkin; V A Morgan; S L Giles; S F Riches; C Parker; N M deSouza
Journal:  Br J Radiol       Date:  2013-02-20       Impact factor: 3.039

Review 10.  Diffusion-weighted imaging with apparent diffusion coefficient mapping and spectroscopy in prostate cancer.

Authors:  Michael A Jacobs; Ronald Ouwerkerk; Kyle Petrowski; Katarzyna J Macura
Journal:  Top Magn Reson Imaging       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.